Structure Therapeutics Inc. (GPCR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 294.24M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 39.84M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -257.81M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $294.24M | (m) | $39.84M | $-257.81M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $248.90M | (m) | $34.71M | $-209.63M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $225.25M | (m) | $28.99M | $-176.56M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $190.05M | (m) | $26.75M | $-247.61M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $163.66M | (m) | $25.28M | $-219.66M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $131.00M | (m) | $21.97M | $-182.52M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $108.81M | (m) | $18.79M | $-158.23M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $95.37M | (m) | $15.06M | $-142.16M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $80.29M | (m) | $10.90M | $-122.47M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $77.65M | (m) | $8.40M | $-115.14M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $70.10M | (m) | $8.19M | $-102.78M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $36.19M | (m) | $2.51M | $-52.56M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |